Literature DB >> 28509087

Postoperative usage of tolvaptan in a patient with aortic valve stenosis complicated by Child-Pugh classification B liver cirrhosis and hepatic edema.

Yasunori Iida1, Tsutomu Ito2, Sachiko Hayashi2, Tatsuo Takahashi2, Takahiko Misumi2.   

Abstract

We report the case of an 80-year-old woman with postoperative congestive heart failure (CHF) complicated by Child-Pugh classification B liver cirrhosis and hepatic edema successfully treated with tolvaptan. The patient suffered from liver cirrhosis and underwent partial hepatectomy for a hepatocellular carcinoma diagnosed together with a severe aortic valve stenosis. Aortic valve replacement was performed under cardiopulmonary bypass. The postoperative course was uneventful until CHF and hepatic edema symptoms appeared on postoperative day (POD) 2. The symptoms were treated with intravenous human atrial natriuretic peptide and oral diuretics. As the condition showed no improvement, oral tolvaptan was administered on POD 11 and thereafter, which markedly improved the symptoms. This is apparently the first report describing the effectiveness of tolvaptan for the postoperative management of fluid balance in a patient with cardiac and liver dysfunction.

Entities:  

Keywords:  Aortic valve stenosis; Competitive vasopressin nonpeptide V2 receptor antagonist; Liver cirrhosis; Tolvaptan

Year:  2014        PMID: 28509087      PMCID: PMC5411630          DOI: 10.1007/s13730-014-0153-y

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  5 in total

1.  Early and late outcome after elective cardiac surgery in patients with cirrhosis.

Authors:  P Bizouarn; A Ausseur; P Desseigne; Y Le Teurnier; B Nougarede; M Train; J L Michaud
Journal:  Ann Thorac Surg       Date:  1999-05       Impact factor: 4.330

2.  Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

Authors:  Mihai Gheorghiade; Cesare Orlandi; John C Burnett; David Demets; Liliana Grinfeld; Aldo Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Christopher Zimmer; Marvin A Konstam
Journal:  J Card Fail       Date:  2005-05       Impact factor: 5.712

3.  Risk prediction and outcomes in patients with liver cirrhosis undergoing open-heart surgery.

Authors:  Matthias Thielmann; Achmet Mechmet; Markus Neuhäuser; Daniel Wendt; Paschalis Tossios; Ali Canbay; Parwis Massoudy; Heinz Jakob
Journal:  Eur J Cardiothorac Surg       Date:  2010-04-21       Impact factor: 4.191

4.  Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.

Authors:  Isao Sakaida; Satoyoshi Yamashita; Tomoo Kobayashi; Masafumi Komatsu; Terufumi Sakai; Yasuji Komorizono; Mitsuru Okada; Kiwamu Okita
Journal:  J Int Med Res       Date:  2013-05-17       Impact factor: 1.671

5.  V2 receptor antagonist; tolvaptan.

Authors:  Joo-Hark Yi; Hyun-Jong Shin; Ho-Jung Kim
Journal:  Electrolyte Blood Press       Date:  2011-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.